provides innovative products and therapies for use by medical professionals to meet the health care needs of their patients.
Liability Adjusted Cash Flow Yield
Dividend Acid Test:
TheStreet Ratings' Grade
: Buy (B-) -- Medtronic's gross profit margin for the second quarter of its fiscal year 2011 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. Medtronic has average liquidity. Currently, the Quick Ratio is 1.27, which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
During the same period, stockholders' equity ("net worth") has increased by 12.91% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.